Impairment of In Vitro and In Vivo Heart Function in Angiotensin-(1-7) Receptor Mas Knockout Mice
about
Update on RAAS Modulation for the Treatment of Diabetic Cardiovascular DiseasePhysiology of kidney reninAngiotensin1-9 antagonises pro-hypertrophic signalling in cardiomyocytes via the angiotensin type 2 receptorEvidence that the vasodilator angiotensin-(1-7)-Mas axis plays an important role in erectile functionImpairment of cardiac function and remodeling induced by myocardial infarction in rats are attenuated by the nonpeptide angiotensin-(1-7) analog AVE 0991.Amelioration of cardiac function and activation of anti-inflammatory vasoactive peptides expression in the rat myocardium by low level laser therapy.Therapeutic implications of the vasoprotective axis of the renin-angiotensin system in cardiovascular diseases.Infusion of angiotensin-(1-7) reduces glomerulosclerosis through counteracting angiotensin II in experimental glomerulonephritisTargeting the vasoprotective axis of the renin-angiotensin system: a novel strategic approach to pulmonary hypertensive therapy.The novel Mas agonist, CGEN-856S, attenuates isoproterenol-induced cardiac remodeling and myocardial infarction injury in rats.MAS promoter regulation: a role for Sry and tyrosine nitration of the KRAB domain of ZNF274 as a feedback mechanism.Stabilization of the angiotensin-(1-7) receptor Mas through interaction with PSD95.Beneficial effects of the activation of the angiotensin-(1-7) MAS receptor in a murine model of adriamycin-induced nephropathy.Angiotensin-converting enzyme 2 activation protects against hypertension-induced cardiac fibrosis involving extracellular signal-regulated kinases.Atypical signaling and functional desensitization response of MAS receptor to peptide ligands.Soluble angiotensin-converting enzyme 2 in human heart failure: relation with myocardial function and clinical outcomes.Angiotensin converting enzyme 2, Angiotensin-(1-7), and receptor MAS axis in the kidney.Beneficial effects of long-term administration of an oral formulation of Angiotensin-(1-7) in infarcted rats.MAS C-Terminal Tail Interacting Proteins Identified by Mass Spectrometry- Based Proteomic Approach.Angiotensin-(1-7)-mediated signaling in cardiomyocytes.Angiotensin-(1-7) Attenuates Kidney Injury Due to Obstructive Nephropathy in Rats.International Union of Basic and Clinical Pharmacology. XCIX. Angiotensin Receptors: Interpreters of Pathophysiological Angiotensinergic Stimuli [corrected].Modulation of cardiac L-type Ca2+ current by angiotensin-(1-7): normal versus heart failureACE2, angiotensin-(1-7) and Mas receptor axis in inflammation and fibrosis.Angiotensin-(1-7)/mas inhibits apoptosis in alveolar epithelial cells through upregulation of MAP kinase phosphatase-2.Upregulation of the angiotensin-converting enzyme 2/angiotensin-(1-7)/Mas receptor axis in the heart and the kidney of growth hormone receptor knock-out mice.Role of the ACE2/Angiotensin 1-7 Axis of the Renin-Angiotensin System in Heart FailureAngiotensin converting enzyme 2 (ACE2) activity in fetal calf serum: implications for cell culture research.New angiotensins.Effect of angiotensin receptor blockade on endothelial function: focus on olmesartan medoxomilDistinct roles for angiotensin-converting enzyme 2 and carboxypeptidase A in the processing of angiotensins within the murine heartDevil and angel in the renin-angiotensin system: ACE-angiotensin II-AT1 receptor axis vs. ACE2-angiotensin-(1-7)-Mas receptor axis.Novel neurohormonal insights with therapeutic potential in chronic heart failure.ACE2: more of Ang-(1-7) or less Ang II?Recombinant human angiotensin-converting enzyme 2 as a new renin-angiotensin system peptidase for heart failure therapy.The renin-angiotensin-aldosterone system in 2011: role in hypertension and chronic kidney disease.New cardiovascular and pulmonary therapeutic strategies based on the Angiotensin-converting enzyme 2/angiotensin-(1-7)/mas receptor axis.Angiotensin-(1-7): beyond the cardio-renal actions.Angiotensin-converting enzyme 2 and angiotensin 1-7: novel therapeutic targets.Neuropeptides: metabolism to bioactive fragments and the pharmacology of their receptors.
P2860
Q28077454-1F875299-1B16-4157-825B-AEF6313AD868Q28279771-FF48F1AB-BDB5-4BB5-817C-BABF994D4410Q28566391-46B836FC-44B9-454D-8DC3-E19CA4A564FAQ28566424-8E13086D-99A6-4D59-9793-8E20528DB315Q29346972-73C7B456-0A26-475B-B48C-4F31996C851CQ31171637-AD7D05FB-4CDC-4325-8015-79A22E4ACD30Q33677369-20FAE564-B7E0-4152-A320-3FC25EE15552Q33727783-58B2F60D-C5AE-4870-84C1-F5B59860B7BDQ34215319-2EE532A7-77C9-4760-BFA5-520E1B453344Q34613227-BB8A2732-1391-4A32-955C-966EFB423E21Q34632694-299C41A1-A9A4-421F-800D-E61E4ECFAD36Q34735823-7BA51A82-3E1A-4BB0-BFB6-D24A10730AF6Q34770468-0F0A85BC-5F41-41D0-BE21-07EE354D83D8Q34799585-9094EC15-F088-4B2C-9BE7-0C396877DEE3Q35214181-79AE4902-A182-43D0-B3E1-329A6E38CC17Q35229766-D6E9AB6A-6B28-412C-B883-5F8CD64D8FFAQ35810568-A97CD011-7EB1-4F30-A2A5-ED39F0056605Q35811007-6314AC47-6456-4624-AA95-439839AC84A7Q35814372-33A1D9C0-DADA-4AA9-960F-2520A03555A3Q35829928-1A8095A6-9AC7-466B-89D8-FD8D21319072Q35838004-405B849A-1768-413C-B47D-877DDDE1F5BCQ36241932-44343D46-7276-4230-8EB4-B07A910B2F14Q36697674-FC89E141-0415-49FB-AA20-EAE83C3FAA75Q36929414-5B793219-A926-4244-9DB9-2E18395536C0Q36955317-1E745FCD-88EF-49F0-ABD6-47F149A840BCQ36974726-E25B9BB3-86B1-49AE-A322-41D54E800883Q37081415-76483570-FD40-444B-A955-72DB72857DBAQ37120331-F5426485-9FB2-4A4F-AD78-0902921B889FQ37147841-199DC584-E45A-42A4-B734-1B775317C30EQ37167510-B8CA0BB5-7945-4FDD-BF6A-9EB2F99CA187Q37175696-25E6C0D8-3152-4728-ABA3-FBDC61D0FB03Q37492223-4CBE3457-3BA1-4D48-906A-A966FE217271Q37749836-782B05C3-0438-4759-879A-DD7EF7F6CFC7Q37806553-A728881C-6F60-4E20-AC6B-2FE95130B080Q37879608-C908CB02-8CD2-443B-8940-0F34D24DBD85Q37938867-FB38D45A-4AB4-402D-84CA-AE51D38BD6A1Q37982718-63BB085C-3786-425A-8832-820F4C871C8EQ38068237-3580BBFC-C971-4774-A867-A58CFB00F767Q38207841-D4AF0836-C825-4AF2-AF0C-497254A8CAFAQ38217456-F339A8C4-B445-40B8-97AA-F4FD16F0A180
P2860
Impairment of In Vitro and In Vivo Heart Function in Angiotensin-(1-7) Receptor Mas Knockout Mice
description
im März 2006 veröffentlichter wissenschaftlicher Artikel
@de
scientific article published on 27 March 2006
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована в травні 2006
@uk
name
Impairment of In Vitro and In Vivo Heart Function in Angiotensin-
@nl
Impairment of In Vitro and In ...... -7) Receptor Mas Knockout Mice
@en
type
label
Impairment of In Vitro and In Vivo Heart Function in Angiotensin-
@nl
Impairment of In Vitro and In ...... -7) Receptor Mas Knockout Mice
@en
prefLabel
Impairment of In Vitro and In Vivo Heart Function in Angiotensin-
@nl
Impairment of In Vitro and In ...... -7) Receptor Mas Knockout Mice
@en
P2093
P50
P1433
P1476
Impairment of in vitro and in ...... -7) receptor MAS knockout mice
@en
P2093
Alvair P Almeida
Anderson J Ferreira
Anderson S Ramos
Carlos H Castro
Elisandra Gava
Kaleizu T Rosa
Maria C Irigoyen
Natalia Alenina
Renata Dutra de Paula
Sérgio V B Pinheiro
P304
P356
10.1161/01.HYP.0000215289.51180.5C
P407
P577
2006-03-27T00:00:00Z